Related Experiment Videos
Erythromycin versus tetracycline for treatment of Mediterranean spotted fever
Insights
Tetracycline hydrochloride demonstrated superior efficacy over erythromycin stearate in treating Mediterranean spotted fever in children. Tetracycline led to faster symptom resolution and shorter fever duration, especially when initiated early.
Area of Science:
- Pediatric Infectious Diseases
- Bacterial Infections
- Pharmacological Treatments
Background:
- Mediterranean spotted fever (MSF) is a tick-borne illness requiring effective antibiotic treatment.
- Choosing the optimal antibiotic is crucial for rapid recovery and preventing complications.
Purpose of the Study:
- To compare the efficacy of tetracycline hydrochloride and erythromycin stearate in treating Mediterranean spotted fever in children.
- To evaluate the speed of clinical symptom resolution and fever reduction with each antibiotic.
Main Methods:
- A randomized comparative trial involving 81 children aged 1-13 years.
- Participants were treated with either tetracycline hydrochloride or erythromycin stearate.
- Clinical outcomes, including fever duration and symptom resolution, were monitored.
Main Results:
- Both tetracycline and erythromycin were effective treatments for MSF.
- Tetracycline hydrochloride resulted in significantly faster disappearance of clinical symptoms and fever.
- Early treatment (within 72 hours) with tetracycline showed a significantly shorter febrile period.
Conclusions:
- Tetracycline hydrochloride appears to be superior to erythromycin stearate for treating Mediterranean spotted fever in children.
- Prompt initiation of tetracycline treatment may lead to more rapid recovery.
Abstract:
Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever.